glp 1 agonist and depression GLP-1 receptor agonists attenuate depressive symptoms through multiple Now, new research suggests that

In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Clin Perinatol 2000

Evidence remains limited and more robust studies are required

Its pharmaceutical equivalent, Afamelanotide (Scenesse), was developed by Clinuvel Pharmaceuticals and received EMA approval in 2014 and FDA approval in 2019 for erythropoietic protoporphyria making it the only melanocortin peptide with regulatory approval

10.1056/NEJMoa043160 38 RamaekersV